8HH Stock Overview A medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Avanos Medical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Avanos Medical Historical stock prices Current Share Price US$15.30 52 Week High US$22.00 52 Week Low US$15.20 Beta 0.96 1 Month Change -16.39% 3 Month Change -26.44% 1 Year Change -21.94% 3 Year Change -50.32% 5 Year Change -49.67% Change since IPO -48.65%
Recent News & Updates Avanos Medical, Inc. Appoints Warren Machan as Interim Chief Financial Officer Dec 04
Investor sentiment deteriorates as stock falls 15% Nov 06 Avanos Medical, Inc. Launches New CORGRIP SR
Third quarter 2024 earnings released: EPS: US$0.13 (vs US$0.19 loss in 3Q 2023) Nov 01 Avanos Medical, Inc. Announces Chief Executive Officer Changes
Avanos Medical, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 23 See more updates Avanos Medical, Inc. Appoints Warren Machan as Interim Chief Financial Officer Dec 04
Investor sentiment deteriorates as stock falls 15% Nov 06 Avanos Medical, Inc. Launches New CORGRIP SR
Third quarter 2024 earnings released: EPS: US$0.13 (vs US$0.19 loss in 3Q 2023) Nov 01 Avanos Medical, Inc. Announces Chief Executive Officer Changes
Avanos Medical, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 23
Second quarter 2024 earnings released: EPS: US$0.094 (vs US$0.092 loss in 2Q 2023) Aug 01
Avanos Medical, Inc. Provides Earnings Guidance for the Full Year 2024 Jul 31
Avanos Medical, Inc. Appoints Indrani Franchini to its Board of Directors Jul 01
Avanos Medical, Inc. Appoints Sigfrido (Sig) Delgado as Senior Vice President, Integrated Supply Chain May 15
Avanos Medical, Inc. Provides Earnings Guidance for the Year 2024 May 03
First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.17 loss in 1Q 2023) May 02
Avanos Medical, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 27
Senior VP recently sold €140k worth of stock Mar 17
Avanos Medical, Inc., Annual General Meeting, Apr 25, 2024 Mar 16 Avanos Medical, Inc. Announces Voluntary Recall of Mic Gastric - Jejunal Feeding Tube Kits Feb 22
Full year 2023 earnings released: US$0.21 loss per share (vs US$1.08 profit in FY 2022) Feb 22
Avanos Medical, Inc. Provides Earnings Guidance for 2024 Feb 21
Investor sentiment deteriorates as stock falls 20% Jan 06
Avanos Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Jan 05
Investor sentiment improves as stock rises 20% Nov 08
Avanos Medical, Inc. Provides Financial Guidance for the Year 2023 Nov 03
New minor risk - Profit margin trend Nov 02
Avanos Medical, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 26
New minor risk - Earnings quality Aug 11
Avanos Medical, Inc. Provides Earnings Guidance for the Year 2023 Aug 10
Second quarter 2023 earnings released: US$0.092 loss per share (vs US$0.24 profit in 2Q 2022) Aug 10 Avanos Medical, Inc. to Report Q2, 2023 Results on Aug 09, 2023
Avanos Medical, Inc.(NYSE:AVNS) dropped from Russell 2000 Dynamic Index Jun 25
Avanos Medical, Inc. (NYSE:AVNS) entered into a definitive agreement to acquire Diros Technology Inc. Jun 20
SunMed, LLC entered into a Purchase Agreement to acquire Respiratory Health Business from Avanos Medical, Inc. (NYSE:AVNS) for $110 million. Jun 09
Investor sentiment deteriorates as stock falls 19% May 10
First quarter 2023 earnings released: US$0.011 loss per share (vs US$0.12 profit in 1Q 2022) May 03
Full year 2022 earnings released: EPS: US$1.08 (vs US$0.11 in FY 2021) Feb 22
Avanos Medical, Inc. Announces Resignation of Arjun R. Sarker as Senior Vice President, Effective May 10, 2023 Feb 18
Avanos Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 15
Avanos Medical, Inc. Announces Executive Changes Jan 12
Insufficient new directors Nov 16
Avanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain & Procurement Nov 15
Third quarter 2022 earnings released: EPS: US$0.34 (vs US$0.73 loss in 3Q 2021) Nov 03
Avanos Medical, Inc. Affirms Revenue Guidance for the Full-Year 2022 Nov 03
Avanos Medical, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 27
Avanos Medical, Inc. Announces Resignation of Maria Sainz, Member of the Board of Directors, Effective January 1, 2023 Oct 12
Second quarter 2022 earnings released: EPS: US$0.24 (vs US$0.79 in 2Q 2021) Aug 10
Avanos Medical, Inc. Provides Earnings Outlook for the Full Year 2022 Aug 10
Avanos Medical, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Avanos Medical, Inc. (NYSE:AVNS) announces an Equity Buyback for $25 million worth of its shares. May 18
First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.16 loss in 1Q 2021) May 05
Avanos Medical, Inc. Affirms Earnings Guidance for the Year 2022 May 05
Insufficient new directors Apr 27
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Avanos Medical, Inc. Provides Sales Guidance for the Full Year 2022 Feb 24
Avanos Medical, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 16
Forecast breakeven date pushed back to 2022 Dec 31
Avanos Medical, Inc. (NYSE:AVNS) announces an Equity Buyback for $30 million worth of its shares. Dec 16
Insufficient new directors Dec 06
Third quarter 2021 earnings released: US$0.73 loss per share (vs US$0.40 profit in 3Q 2020) Nov 04
Forecast to breakeven in 2021 Nov 04
Independent Director recently bought €134k worth of stock Sep 17
Avanos Medical, Inc. Provides Earnings Guidance for the Full Year 2021 Aug 05
Independent Director Heidi Fields has left the company Aug 05
Second quarter 2021 earnings released: EPS US$0.79 (vs US$0.063 loss in 2Q 2020) Aug 04
Avanos Medical, Inc. Announces Net Sales Guidance for 2021 May 08
Avanos Medical, Inc., Annual General Meeting, Apr 29, 2021 Mar 20
Avanos Medical, Inc. Provides Earnings Guidance for the Year 2021 Feb 19
Avanos Medical, Inc. to Report Q4, 2020 Results on Feb 18, 2021 Feb 12
New 90-day high: €40.60 Feb 11 Avanos Medical, Inc. Announces Appointments
Avanos Medical, Inc. to Report Q3, 2020 Results on Nov 03, 2020 Oct 28
Avanos Medical, Inc. Announces Management Changes Oct 27
Avanos Medical, Inc. Not to Provided Guidance for the Full Year 2020 Aug 06 Avanos Medical, Inc. (NYSE:AVNS) completed the acquisition of substantially all assets of Summit Medical Products Inc. $17.3 million. Shareholder Returns 8HH DE Medical Equipment DE Market 7D -0.6% -1.5% 0.7% 1Y -21.9% -7.0% 8.4%
See full shareholder returns
Return vs Market: 8HH underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is 8HH's price volatile compared to industry and market? 8HH volatility 8HH Average Weekly Movement 7.4% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 8HH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8HH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 2014 3,771 Michael Greiner avanos.com
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems.
Show more Avanos Medical, Inc. Fundamentals Summary How do Avanos Medical's earnings and revenue compare to its market cap? 8HH fundamental statistics Market cap €669.53m Earnings (TTM ) €21.14m Revenue (TTM ) €664.05m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8HH income statement (TTM ) Revenue US$681.50m Cost of Revenue US$303.20m Gross Profit US$378.30m Other Expenses US$356.60m Earnings US$21.70m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 11:49 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Avanos Medical, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ravi Misra Berenberg Kristen Stewart CL King & Associates, Inc. Kristen Stewart Deutsche Bank
Show 7 more analysts 
